BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38007341)

  • 1. Evaluation of the humoral response to the third dose of SARS-COV-2 vaccines in liver transplant recipients.
    Ducasa N; Benencio P; Mauro E; Anders M; Mazzitelli B; Bleichmar L; Quiroga MF; Barbero M; Cairo F; Alter A; Etcheves P; Scarton G; Sobenko N; Biglione M; Mendizabal M
    Vaccine; 2023 Dec; 41(52):7663-7670. PubMed ID: 38007341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.
    Benning L; Morath C; Bartenschlager M; Kim H; Reineke M; Beimler J; Buylaert M; Nusshag C; Kälble F; Reichel P; Töllner M; Schaier M; Klein K; Benes V; Rausch T; Rieger S; Stich M; Tönshoff B; Weidner N; Schnitzler P; Zeier M; Süsal C; Hien Tran T; Bartenschlager R; Speer C
    Am J Transplant; 2022 Jul; 22(7):1873-1883. PubMed ID: 35384272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients.
    Gallais F; Renaud-Picard B; Solis M; Laugel E; Soulier E; Caillard S; Kessler R; Fafi-Kremer S
    J Heart Lung Transplant; 2022 Oct; 41(10):1429-1439. PubMed ID: 35953352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of humoral immunogenicity in solid organ transplant recipients after third-dose mRNA vaccine with homologous or heterologous schedules: An observational study.
    Kang JM; Lee J; Huh KH; Joo DJ; Lee JG; Kim HY; Lee M; Jung I; Kim MY; Kim S; Park Y; Kim MS
    J Clin Virol; 2023 Feb; 159():105374. PubMed ID: 36592547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients.
    Zhang L; Yang J; Lai C; Wan L; Xiong S; Kong W; Liu Z; Yu P; Chen M; Mai W; Khan SA; Deng M; Chen L; Lei Y; Zhou Q; Yu N; Li P; Chen Z; Ji T
    Front Immunol; 2022; 13():1042784. PubMed ID: 36700230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients.
    Karaba AH; Zhu X; Liang T; Wang KH; Rittenhouse AG; Akinde O; Eby Y; Ruff JE; Blankson JN; Abedon AT; Alejo JL; Cox AL; Bailey JR; Thompson EA; Klein SL; Warren DS; Garonzik-Wang JM; Boyarsky BJ; Sitaras I; Pekosz A; Segev DL; Tobian AAR; Werbel WA
    Am J Transplant; 2022 Apr; 22(4):1253-1260. PubMed ID: 34951746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response.
    Karaba AH; Johnston TS; Aytenfisu TY; Akinde O; Eby Y; Ruff JE; Abedon AT; Alejo JL; Blankson JN; Cox AL; Bailey JR; Klein SL; Pekosz A; Segev DL; Tobian AAR; Werbel WA
    Transplantation; 2022 Jul; 106(7):1440-1444. PubMed ID: 35417115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.
    Ahmed-Belkacem A; Redjoul R; Brillet R; Ahnou N; Leclerc M; López-Molina DS; Soulier A; Gourgeon A; Rodriguez C; Maury S; Pawlotsky JM; Fourati S
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients.
    Charmetant X; Espi M; Benotmane I; Barateau V; Heibel F; Buron F; Gautier-Vargas G; Delafosse M; Perrin P; Koenig A; Cognard N; Levi C; Gallais F; Manière L; Rossolillo P; Soulier E; Pierre F; Ovize A; Morelon E; Defrance T; Fafi-Kremer S; Caillard S; Thaunat O
    Sci Transl Med; 2022 Mar; 14(636):eabl6141. PubMed ID: 35103481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS-CoV-2 mRNA vaccine.
    Borgogna C; Ferrante D; Rosso G; Guglielmetti G; Lo Cigno I; Raviola S; Caneparo V; Quaglia M; Cantaluppi V; Gariglio M
    J Med Virol; 2024 Jun; 96(6):e29710. PubMed ID: 38804187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
    Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
    JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 vaccine in liver transplant recipients.
    Meunier L; Sanavio M; Dumortier J; Meszaros M; Faure S; Ursic Bedoya J; Echenne M; Boillot O; Debourdeau A; Pageaux GP
    Liver Int; 2022 Aug; 42(8):1872-1878. PubMed ID: 35338550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern.
    Lafon E; Jäger M; Bauer A; Reindl M; Bellmann-Weiler R; Wilflingseder D; Lass-Flörl C; Posch W
    J Allergy Clin Immunol; 2022 Apr; 149(4):1242-1252.e12. PubMed ID: 35093484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses' Vaccinated Solid Organ Transplant Recipients.
    Busà R; Russelli G; Miele M; Sorrentino MC; Di Bella M; Timoneri F; Di Mento G; Mularoni A; Vitulo P; Conaldi PG; Bulati M
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine.
    Sheng WH; Ieong SM; Lin PH; Hsieh MJ; Yang HC; Pan CF; Chao TL; Chang SY; Chang SC
    J Formos Med Assoc; 2023 Feb; 122(2):121-131. PubMed ID: 36127206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects.
    Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M
    Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients.
    Luxenburger H; Reeg DB; Lang-Meli J; Reinscheid M; Eisner M; Bettinger D; Oberhardt V; Salimi Alizei E; Wild K; Graeser A; Karl V; Sagar ; Emmerich F; Klein F; Panning M; Huzly D; Bengsch B; Boettler T; Elling R; Thimme R; Hofmann M; Neumann-Haefelin C
    J Hepatol; 2023 May; 78(5):1017-1027. PubMed ID: 36804404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.